Tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. This phase 3 randomized, double-blind study evaluated pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT.
Pexidartinib is the first systemic therapy to demonstrate a robust tumor response in TGCT with improved patient symptoms and functional outcomes; mixed and cholestatic hepatotoxicity is an identified risk.
Copyright remains with the authors and publisher.
Tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. This phase 3 randomized, double-blind study evaluated pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT.
Pexidartinib is the first systemic therapy to demonstrate a robust tumor response in TGCT with improved patient symptoms and functional outcomes; mixed and cholestatic hepatotoxicity is an identified risk.
Copyright remains with the authors and publisher.